Clinical and immunological peculiarities of ARVI in patients with concomitant allergic rhinitis in remission


DOI: https://dx.doi.org/10.18565/therapy.2024.7.50-57

Ponezheva L.O., Turapova A.N., Mannanova I.V., Alakaev R.Z., Vyzhlova E.N., Bragina G.S., Kalyuzhin O.V.

1) I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University); 2) Central Research Institute of Epidemiology of Rospotrebnadzor, Moscow; 3) Institute of Dentistry and Maxillofacial Surgery of Kh.M. Berbekov Kabardino-Balkarian State University, Nalchik; 4) National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Healthcare of Russia, Moscow
Abstract. Combination of acute respiratory viral infection (ARVI) and allergy is characterized by a complex interaction and mutual influence of two pathological processes.
The aim: to find clinical and immunological peculiarities of seasonal ARVI in patients with concomitant allergic rhinitis (AR) in the remission stage, to determine the efficacy of various drug therapy options in such kind of patients.
Material and methods. 88 patients with uncomplicated ARVI were involved in the study. Group 1 included 32 persons with ARVI and seasonal AR who received recombinant interferon alpha-2b (IFN- α-2b) with antioxidants (VIFERON®). The same treatment regimen was received by the 2nd group of 29 patients with ARVI without allergy. Group 3 included 27 persons with ARVI without allergy who used umifenovir. The control group consisted of 30 conditionally healthy individuals.
Results. Concentration of IFN-α in the blood serum and the proportion of cells expressing CD118+ among peripheral blood lymphocytes in patients with ARVI + AR before treatment significantly exceeded this index in conditionally healthy patients. In patients with ARVI without allergy, the level of induced IFN-α production was significantly higher than in conditionally healthy patients and patients with ARVI and AR. After treatment, in both groups, concentration of serum and induced IFN-α decreased to the conditional norm, there was a tendency for increasing the levels of CD118+ and CD119+.
Conclusion. In the early stages of ARVI development, patients with AR in remission were found to have a decreased ability of blood cells to produce IFN types I and II in response to stimulation comparatively to patients without allergy. Comparison of the clinical efficacy of two treatment options in patients with ARVI revealed that the combination of nasal and rectal forms of recombinant IFN-α-2b with antioxidants (VIFERON®) is more effective than use of umifenovir in stopping clinical manifestations of ARVI in the presence of almost identical virological efficacy.

Literature


1. Wise S.K., Damask C., Roland L.T. et al. International consensus statement on allergy and rhinology: Allergic rhinitis. Int Forum Allergy Rhinol. 2023; 13(4): 293–859.


https://doi.org/10.1002/alr.23090. PMID: 36878860.


2. Thomas C., Moraga I., Levin D. et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell. 2011; 146(4): 621–32.


https://doi.org/10.1016/j.cell.2011.06.048. PMID: 21854986. PMCID: PMC3166218.


3. Калюжин О.В. ОМ-85 в профилактике/лечении респираторных инфекций и обострений хронических заболеваний легких: критерии выбора, механизмы и доказательства. Лечащий врач. 2018; (3): 77. (Kalyuzhin O.V. OM-85 in the prevention/treatment of respiratory infections and exacerbations of chronic lung diseases: Selection criteria, mechanisms and evidence. Lechaschiy vrach = Attending Physician. 2018; (3): 77 (In Russ.)). EDN: YSJNTU.


4. Горелов А.В., Понежева Ж.Б., Турапова А.Н. с соавт. Острые респираторные вирусные инфекции в схемах и таблицах: учебно-методическое пособие для врачей. М.: Медконгресс. 2022; 44 с. (Gorelov A.V., Ponezheva Zh.B., Turapova A.N. et al. Acute respiratory viral infections in charts and tables. Educational and methodical manual for doctors. Moscow: Medkongress. 2022; 44 pp. (In Russ.)). ISBN: 978-5-6047195-0-3.


5. Себекина О.В., Передкова Е.В., Ненашева Н.М., Гребенникова Ю.В. Аллергический ринит в период пандемии коронавирусной инфекции: сложности диагностики и особенности терапии. Медицинский совет. 2020; (17): 132–140. (Sebekina O.V., Peredkova E.V., Nenasheva N.M., Grebennikova Yu.V. Allergic rhinitis during a coronavirus pandemic: Difficulties of diagnosis and features of therapy. Meditsinskiy sovet = Medical Council. 2020; (17): 132–140 (In Russ.)).


https://doi.org/10.21518/2079-701X-2020-17-132-140. EDN: YEGYYV.


6. Калюжин О.В. Острые респираторные вирусные инфекции: современные вызовы, новый взгляд на место индукторов интерферонов в профилактике и терапии. Лечащий врач. 2013; (9): 78–84. (Kalyuzhin O.V. Acute respiratory viral infections: Modern challenges, a new look at the place of interferon inducers in prevention and therapy. Lechaschiy vrach = Attending Physician. 2013; (9): 78–84 (In Russ.)). EDN: TAFMVH.


7. Wang S.Z., Ma F.M., Zhao J.D. Expressions of nuclear factor-kappa B p50 and p65 and their significance in the up-regulation of intercellular cell adhesion molecule-1 mRNA in the nasal mucosa of allergic rhinitis patients. Eur Arch Otorhinolaryngol. 2013; 270(4): 1329–34.


https://doi.org/10.1007/s00405-012-2136-y. PMID: 23053371.


8. Zaman M., Chandrudu S., Toth I. Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res. 2013; 3(1): 100–9.


https://doi.org/10.1007/s13346-012-0085-z. PMID: 23316448. PMCID: PMC3539070.


9. Караулов А.В., Ликов В.Ф. Иммунотерапия респираторных заболеваний. Руководство для врачей. М.: Издательство отделения РАЕН «Лекарства и пищевые добавки». 2004; 32 с. (Karaulov A.V., Likov V.F. Immunotherapy of respiratory diseases. A guide for physicians Мoscow: Publishing House of the Department of the Russian Academy of Natural Sciences “Medicines and dietary supplements”. 2004; 32 pp. (In Russ.)). ISBN: 5-901308-07-7.


10. Караулов А.В., Калюжин О.В. Иммунотерапия инфекционных болезней: проблемы и перспективы. Терапевтический архив. 2013; 85(11): 100–108. (Karaulov A.V., Kalyuzhin O.V. Immunotherapy of infectious diseases: Problems and prospects. Terapevticheskiy arkhiv = Therapeutic Archive. 2013; 85(11): 100–108 (In Russ.)). EDN: RTKZHV.


11. Царев С.В. Инфекция и аллергия: взаимосвязь и взаимовлияние. РМЖ. 2016; 24(12): 800–803. (Tsarev S.V. Infection and allergy: Interrelation and mutual influence. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2016; 24(12): 800–803 (In Russ.)). EDN: WHKNQL.


12. Григорян С.С., Майоров И.А., Иванова А.М., Ершов Ф.И. Оценка интерферонового статуса людей по пробам цельной крови. Вопросы вирусологии. 1988; 33(4): 433–436. (Grigoryan S.S., Mayorov I.A., Ivanova A.M., Ershov F.I. Assessment of interferon status in humans using whole blood samples. Voprosy virusologii = Problems of Virology. 1988; 33(4): 433–436 (In Russ.)).


13. Калюжин О.В. Острые респираторные вирусные инфекции: современные вызовы, противовирусный ответ, иммунопрофилактика и иммунотерапия. М.: Медицинское информационное агентство. 2014; 144 с. (Kalyuzhin O.V. Acute respiratory viral infections: modern challenges, antiviral response, immunoprophylaxis and immunotherapy. Moscow: Medical Information Agency. 2014; 144 pp. (In Russ.)). ISBN: 978-5-9986-0161-3. EDN: RZQYYX.


14. Fensterl V., Sen G.C. Interferons and viral infections. Biofactors. 2009; 35(1): 14–20.


https://doi.org/10.1002/biof.6. PMID: 19319841.


About the Autors


Liana O. Ponezheva, MD, postgraduate student of the Department of clinical immunology and allergology, I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University). Address: 119048, Moscow, 8/2 Trubetskaya St.
E-mail: ponejevaliana@gmail.com
ORCID: https://orcid.org/000-0001-9459-8143
Alexandra N. Turapova, MD, PhD (Medicine), researcher at the Clinical Department of infectious pathology, Central Research Institute of Epidemiology of Rospotrebnadzor. Address: 111123, Moscow, 3a Novogireevskaya St.
E-mail: alyaspid@gmail.com
ORCID: https://orcid.org/0000-0002-2893-0854
Irina V. Mannanova, MD, PhD (Medicine), scientific researcher at the Clinical Department of infectious pathology, Central Research Institute of Epidemiology of Rospotrebnadzor. Address: 111123, Moscow, 3a Novogireevskaya St.
E-mail: irinasemenova07@rambler.ru
ORCID: https://orcid.org/0000-0003-2244-8810. eLibrary SPIN: 2975-3995
Ramazan Z. Alakaev, 5th-year student of the Institute of Dentistry and Maxillofacial Surgery, Kh.M. Berbekov Kabardino-Balkarian State University. Address: 360004, Nalchik, 135B Tolstogo St.
E-mail: kerimyshka77@gmail.com
ORCID: https://orcid.org/0009-0003-5517-6484
Evgeniya N. Vyzhlova, PhD (Biology), researcher at the Laboratory of ontogenesis and correction of the interferon system, National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Healthcare of Russia. Address: 123098, Moscow, 18 Gamaleуа St.
E-mail: Evizhlova@yandex.ru
ORCID: https://orcid.org/0000-0003-3054-8694
Galina S. Bragina, researcher at the Laboratory of ontogenesis and correction of the interferon system, National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Healthcare of Russia. Address: 123098, Moscow, 18 Gamaleуа St.
E-mail: bragina56@yandex.ru
ORCID: https://orcid.org/0000-0003-4216-5631
Oleg V. Kalyuzhin, MD, Dr. Sci. (Medicine), professor, professor of the Department of clinical immunology and allergology, I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University). Address: 119048, Moscow, 8/2 Trubetskaya St.
E-mail: kalyuzhin@list.ru
ORCID: https://orcid.org/0000-0003-3628-2436


Similar Articles


Бионика Медиа